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Effectiveness of palliative radiotherapy
in patients with non-small cell lung cancer
El˝bieta Chmielewska1, Piotr JaÊkiewicz2
I n t r o d u c t i o n. Lung cancer is the most frequent malignant neoplasm in Poland. During the last 25 years it has become the
first reason of death of men and the second of women in Poland. Patients with non-small cell lung cancer constitute 75% of
all lung cancer patients. The therapy of choice for the advanced, non-small cell lung cancer is radiotherapy with palliative as-
sumption. Many papers indicate that this therapy has no influence on long-term survival, hence it is aimed at reducing the
symptoms. The therapy brings relief to 70-80% of patients. At present no other method with similar effectiveness is known.
The aim of the is study was to assess the effectiveness of palliative radiotherapy as a treatment of the advanced, non-small cell
lung cancer, applied as a remedy for the symptoms resulting from the growth of a lung tumour. Improvement of the quality of
life and long-term survivals were assessed and prognostic factors were analysed.
M a t e r i a l. Between 1990 and 1995, 2330 patients with lung cancer attended the Outpatient Clinic of the Maria Sk∏odow-
ska-Curie Memorial Cancer Center in Warsaw. There were 1948 patients with the non-small cell lung cancer. From this gro-
up 832 patients were qualified to palliative radiotherapy that included the primary tumour. The documentation was found for
803 patients and this group was analysed. The group constituted of 115 women (14.3%) and 688 men (85.7%), aged 28 to 91
(mean 61). In the majority of cases a significant advancement of the disease was found: stage III A in 388 patients (48.3%)
and stage III B in 358 patients (44.6%).
S t a t i s t i c a l  m e t h o d s. Retrospective analysis of the results of the treatment was carried out. The material contained in-
formation on 803 patients. The basis for the analysis was the survival time. It was measured from the starting date of the ir-
radiation to the date of death or the date of the last available information that the patient lives. The survival probability was
calculated with the Kaplan-Meier method. Multidimensional analysis of the relation of the results of the treatment to the ove-
rall state, occurrence of the coexisting diseases, type of the symptoms, previous chemotherapy and histopathological type of the
neoplasm was carried out, using the D.R. Cox proportional risk model. The effectiveness of various dose fractionation methods
were analysed in relation to the improvement. Significance of the differences in this analysis was tested with the logit model.
Re s u l t s. The 12-month survival was 25%±1.5% and the 24-month one was 8%±1% (median: 6 months). In the survival
analysis the following factors had an influence on the results:overall performance status – p=0.00001, superior vena cava syn-
drome – p=0.00001, dyspnoea – p=0.0001, dysphagia – p=0.0016, pain – p=0.01, extensive form of the disease – p=0.03.
On the average 75.3% of the patients observed a reduction of the symptoms, from 60.7% to 91.7%.
C o n c l u s i o n. Palliative radiotherapy in patients with the advanced, non-small cell lung cancer improves the guality of life
in around 75% of cases. The largest improvement in observed in the group of patients qualified to the treatment because of
haemoptysis, dyspnoea, dzsphagia and pain in the chest. The presence of the superior vena cava syndrome has a largest negative
influence on the prognosis. The most significant prognostic factor in the qualification of the patients with the advanced, non-
small cell lung cancer to the palliative treatment is their performance status.
Ocena skutecznoÊci paliatywnego napromieniania Êródpiersia chorych
na niedrobnokomórkowego raka p∏uca
W s t ´ p. Rak p∏uca jest najcz´stszym nowotworem z∏oÊliwym u cz∏owieka. W Polsce w ciàgu ostatniego çwierçwiecza sta∏ si´
pierwszà u m´˝czyzn i drugà u kobiet przyczynà zgonów. Chorzy z rozpoznaniem niedrobnokomórkowego raka p∏uca stano-
wià oko∏o 75% wszystkich chorych na raka p∏uca. Rocznie w Polsce rozpoznajemy go u oko∏o 16 000 chorych. W tej grupie
ponad 70% osób, zg∏aszajàcych si´ po raz pierwszy, jest zdyskwalifikowanych od leczenia operacyjnego i radykalnej radiote-
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Introduction
Lung cancer is the most frequent malignant neoplasm in
man. Its occurrence is strictly related to the exposition
to tobacco smoke, which is a carcinogenic factor. The
risk of cancer is 10-30 times larger in the smokers than in
the non-smokers group. Passive smoking has also a nega-
tive influence, and this influence is larger the younger
the exposed person is [1]. In Poland during the last 25
years, lung cancer became the first reason of death in
men and the second one in women [2]. Between 1968
and 2000 the number of deaths due to lung cancer incre-
ased in men from 18.3% to 34.3% and in women from
3.9% to 8.6% [2].
The results of treatment are still bad, which results
directly from that at the time of disclosure the advance-
ment of the disease is significant. Non-specific clinical
symptoms – cough, chronic pneumonia and fever in
a smoker still do not lead to a suspicion of developing
cancer.
Around 75% of all lung cancer patients have the
non-small cell cancer. In this group over 70% are disquali-
fied from surgery and radical radiotherapy due to the ad-
vancement of the disease [3]. Majority of these patients
have severe clinical symptoms resulting from the presen-
ce of a tumour in the chest. Only 30% do not declare
any symptoms at the time of diagnosis. These patients
are a subject of a long-lasting discussion on the purpose-
fulness of oncological therapy [4-8].
The method of choice for patients with advanced,
non-small cell lung cancer is radiotherapy with the
palliative assuumption. It is aimed at reduction of symp-
toms. Many papers indicate that it has no influence on the
long-term survival [9-11]. The applied treatment brings
improvement in 70-80% of the patients [3, 4, 7, 8, 13].
No other method with a similar effectiveness is known
at present.
The aim of the study
The aim of the study was to assess the effectiveness of the
palliative radiotherapy applied due to symptoms resul-
ting from the growth of a tumour in chest to patients with
advanced, non-small cell lung cancer. The improvement
of the quality of life and the long-term survival were asses-
sed in relation to the overall state of the patient, presen-
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rapii z powodu zaawansowania choroby. U zdecydowanej wi´kszoÊci z nich stwierdza si´ ci´˝kie objawy ze strony guza
w klatce piersiowej. Tylko 30% chorych z tej grupy nie zg∏asza w chwili rozpoznania ˝adnych dolegliwoÊci. Metodà leczenia
z wyboru chorych na zaawansowanego, niedrobnokomórkowego raka p∏uca jest radioterapia o za∏o˝eniu paliatywnym. Ce-
lem jej jest zmniejszenie dolegliwoÊci, gdy˝ wiele prac wskazuje, ˝e nie ma ona wp∏ywu na prze˝ycia odleg∏e. Zastosowane le-
czenie przynosi popraw´ u 70-80% chorych. Aktualnie nie jest znana jakakolwiek inna metoda o podobnej skutecznoÊci.
C e l  p r a c y. Celem pracy by∏a próba oceny skutecznoÊci paliatywnej radioterapii w leczeniu zaawansowanego, niedrobno-
komórkowego raka p∏uca, stosowanej z powodu dolegliwoÊci wynikajàcych ze wzrostu guza w klatce piersiowej. Oceniono po-
praw´ jakoÊci ˝ycia chorych i prze˝ycia odleg∏e. Przeprowadzono analiz´ czynników prognostycznych.
M a t e r i a ∏. W okresie od 1 stycznia 1990 r. do 31 grudnia 1995 r. do Ambulatorium Centrum Onkologii-Insytutu przy ul.
Roentgena 5 w Warszawie zg∏osi∏o si´ 2330 chorych na raka p∏uca, w tym 1948 chorych na niedrobnokomórkowego raka p∏u-
ca. W tej grupie do paliatywnego leczenia napromienianiem, obejmujàcego guz pierwotny, zakwalifikowano 832 chorych. Do
niniejszej pracy odnaleziono dokumentacj´ dla 803 chorych i t´ grup´ poddano analizie. By∏o w niej 115 kobiet (14,3%) i 688
m´˝czyzn (85,7%), w wieku od 28 do 91 lat (Êrednia 61 lat). W wi´kszoÊci przypadków stwierdzano znaczne zaawansowanie
procesu nowotworowego: stopieƒ III A ustalono u 388 chorych (48,3%), a stopieƒ III B u 358 chorych (44,6%).
M e t o d y  s t a t y s t y c z n e. Przeprowadzono retrospektywnà analiz´ wyników leczenia. Materia∏ obejmowa∏ informacje
o 803 chorych. Podstawà oceny wyników by∏ czas prze˝ycia. Czas prze˝ycia liczono od daty rozpocz´cia napromieniania do
daty zgonu lub ostatniej informacji o tym, ˝e chory ˝yje. Prawdopodobieƒstwo prze˝ycia obliczano metodà Kaplana-Meiera.
Przeprowadzono wielowymiarowà analiz´ zale˝noÊci wyników leczenia od stanu ogólnego chorego, wyst´powania chorób
wspó∏istniejàcych, rodzaju zg∏aszanych dolegliwoÊci, uprzedniej chemioterapii i typu histopatologicznego nowotworu, u˝ywa-
jàc modelu proporcjonalnego ryzyka D.R. Coxa. Analizowano skutecznoÊç ró˝nych sposobów frakcjonowania dawki w aspek-
cie wystàpienia poprawy. IstotnoÊç ró˝nic w tej analizie testowano przy pomocy modelu logitowego.
W y n i k i. Prze˝ycie 12 miesi´cy wynios∏o 25%±1,5%, a 24 miesi´cy 8%±1% (mediana: 6 miesi´cy). W analizie prze˝yç na-
st´pujàce parametry mia∏y wp∏yw na uzyskane wyniki: stan ogólny – p=0.00001, zespó∏ ˝y∏y g∏ównej górnej – p=0.00001, dusz-
noÊç – p=0.0001, dysfagia – p=0.0016, ból – p=0.01, postaç rozleg∏a choroby – p=0.03.
Ârednio 75.3% chorych obserwowa∏o zmniejszenie dolegliwoÊci, od 60.7% do 91.7%.
W n i o s k i.  Radioterapia paliatywna u chorych z zawansowanym, niedrobnokomórkowym rakiem p∏uca przynosi popraw´
jakoÊci ˝ycia Êredio w 75% przypadków. Najwi´ksza poprawa obserwowana jest w grupie chorych, kwalifikowanych do lecze-
nia z powodu krwioplucia, dusznoÊci, dysfagii i bulów w klatce piersiowej. Fakt wystàpienia zespo∏u ˝y∏y g∏ównej górnej
w sposób naistotniejszy pogarsza rokowanie. Najistotniejszym czynnikiem rokowniczym w kwalifikacji do leczenia paliatyw-
nego chorych z zaawansowanym, niedrognokomórkowym rakiem p∏uca jest stopieƒ sprawnoÊci chorego.
Key words: palliative radiotherapy, quality of life improvement, non-small cell lung cancer
S∏owa kluczowe: paliatywna radioterapia, poprawa komfortu prze˝ycia, niedrobnokomórkowy rak p∏uca
ce of accompanying diseases, microscopic form of the
cancer, application of the previous neoadjuvant chemo-
therapy and in relation to some other symptoms the most
frequently reported by the patients.
Material
Between January 1, 1990 and December 31, 1995, 2330 patients
with lung cancer attended the Outpatient Clinic of the Maria
Sk∏odowska-Curie Memorial Cancer Center in Warsaw. Among
them there were 1948 patients with the non-small cell lung can-
cer. After clinical investigation and additional diagnostic tests,
832 patients from this group were qualified to palliative radiothe-
rapy, which included the primary tumour (Fig. 1). For the pre-
sent study the documentation of 803 patients was found, and
this group was analysed. The group constituted of 115 women
(14.3%) and 688 men (85.7%), aged from 28 to 91 (mean 61).
All patients underwent physical examinations, radiological inve-
stigation of chest with barite pulp in the oesophagus, broncho-
scopy, routine biochemical blood tests, urine analysis, in a majo-
rity – ultrasound abdomen tests, and in 26% – computed tomo-
graphy of the chest.
Squamous cell carcinoma was diagnosed in 70% of the
patients, adenocarcinoma in 12.3%, large cell cancer in 6.2%
and non-small cell cancer without a precise classification of its ty-
pe in 8.6%. The diagnosis was not established in 2.9%.
The clinical advancement stage was assessed according to
the TNM classification. The advancement of the process is
shown in Tab. I. Severe advancement was diagnosed in a majori-
ty of cases. Symptoms of spread out from the chest were found in
21 patients (2.6%). Two patients had metastases to bones, 14 – to
the supraclavicular lymph nodes, and 2 – to the suprarenal
glands. The features of a second, coexisting neoplasm were fo-
und in 32 (4%) of the remaining patients. A preliminary asses-
sment of the survivals in the two groups was carried out: with
one neoplasm localised in the mediastinum, and with the exten-
sive disease or with a second neoplasm (Fig. 2). No differences
were found; hence, it was decided to incorporate all the pa-
tients in a common analysis.
C l i n i c a l  c h a r a c t e r i s t i c s
The assessment of the overall performance status score of the
patients was performed according to the five-step Zubrod score.
In the analysed group there was 1 patient with score 1, 606 pa-
tients with score 2 (75.5%), 189 with score 3 (23.5%) and 7 pa-
tients with score 4 (0.9%).
The basic criterion for qualification to the treatment was
the presence of symptoms which significantly deteriorated the
quality of life of the patients. These symptoms were shown in
Tab. II.
Tab. II. Symptoms reported by the patients
Symptoms Number of patients
Haemoptysis 109
Pain in the chest 280
Dyspnoea at rest 231
Superior vena cava syndrome 173
Dysphagia 53
In 148 patients (18.4%) the presence of the accompanying
diseases necessitating for systematic treatment and deteriorating
their overall state was found. A previous treatment with cytosta-
tics with the palliative assumption was carried out in 52 patients
(6.2%).
M e t h o d  o f  t r e a t m e n t
Radiotherapy was carried out under the supervision of the same
group of physicians. A technique of two opposite fields was ap-
plied – the anterior and the posterior one. The irradiated region
comprised the primary lesion with a 2 cm margin for the pa-
tients in a bad overall state (Zubrod 3 and 4). With this me-
thod 231 patients were treated (28.8%). For the patients in
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Fig. 1. Therapy in the group of 2330 patients examined for the first ti-
me between 1.01.1990 and 31.12.1995
Fig. 2. Survival probability of patients irradiated palliatively to media-
stinum because of an advanced, non-small cell lung cancer, in the gro-
up of patients with the localised disease (750 patients) and in the gro-
up with the spread disease (53 patients)
Tab. I. Clinical stage of the cancer in the analysed group
Clinical stage Number of patients Percentage
I 2 0.2
II 55 6.8
III A 388 48.3
III B 337 41.9
IV 21 2.6
a better overall state, with better survival prognosis, the neighbo-
uring mediastinum region was additionally included into the ir-
radiation field. In this way 572 patients were treated (71.2%). In
227 patients (28.%) a single irradiation series, administering
a dose of 20 Gy in 5 fraction was given, in 43 patients (5.4%) two
series were performed with a total dose of 40 Gy in 5 fractions, in
298 patients (31.7%) 30 Gy in 10 fractions were given, and in 187
patients (23.3%) 22 Gy were given in 4 fractions. The rema-
ining 48 patients (5.9%) received one fraction of 8 or 9 Gy, repe-
ated after a one-week break according to the need. The fractio-
nation method depended on the overall state of the patient: pa-
tients with a worse overall state received single fractions or were
qualified to one irradiation series up to a total dose of 20 or 22
Gy. The total dose was calculated according to the ICRU recom-
mendations in the middle of the AP dimension in the central ra-
dius for AP fields. The irradiation was carried out with the Co-
balt 60 gamma beams, or photon X beams with energies of 4, 9
and 15 MeV from linear accelerators. In 53 patients the treat-
ment was broken due to the aggravation of the overall state.
These patients were included in the analysis.
After the treatment the patients were systematically follo-
wed-up: the group with worse prognosis in monthly intervals
and the remaining group in 2 or 3-month intervals.
Statistical method
The source for the retrospective analysis of the clinical
material were the case histories. The observation was clo-
sed on June 31, 2000. For all the patients the information
whether the patient was alive, and if not, the date of de-
ath, was known. The basic information for the assessment
of results was the survival time.
The survival time was measured from the starting
date of irradiation to the date of death or the date of
the last information that the patient lives. Survival proba-
bility was calculated with the Kaplan-Meier method [14].
The statistical significance α=0,05 was assumed. The as-
sumptions of the model were verified with the graphic
methods. The information about the improvement was
received from the patients. In this way the group of
patients in which the radiotherapy gave an improvement
of the quality of life was assessed. Multivariate analysis of
prognostic factors was carried out with the use of the
D.R. Cox proportional risk model [15]. The considered
factors were: Zubrod score, presence of the coexisting di-
seases, previous chemotherapy, type of symptoms that
were the reason for starting the therapy and the histopa-
thological type of the neoplasm. The final form of the
model was received in the way of a stepwise elimination
of these variables for which the critical test level was lar-
ger than 0.1 (p >0.1). The effectiveness of various dose
fractionation methods in relation to the improvement
was analysed. The significance of the differences in this
analysis was tested with the logit model.
Results
S u r v i v a l s
In the analysed group the probability of a 12-months su-
rvival was 25%±1.5%, and that of a 24-months survival
was 8%±1%, median 6 months. The obtained results are
shown in Fig. 3. The observation period was from 15 to
118 months, mean 11 months, median 6 months. In the in-
vestigated group 703 patients died, all of cancer.
A n a l y s i s  o f  t h e  p r o g n o s t i c  f a c t o r s
The material comprised the information on 803 patients.
The total survival time was analysed. Multidimensional
analysis of the prognostic factors was performed with the
use of the D.R. Cox proportional risk model. The signifi-
cance of the following factors was tested:
– performance status score,
– presence of coexisting diseases,
– previous chemotherapy with the palliative assumption,
– histological type of the cancer,
– various types of symptoms which were the reason of
qualification to the treatment: pain, dysphagia, dyspno-
ea, haemoptysis, superior vena cava syndrome,
– expansive form of the disease (the patients with the
spread outside the chest were also treated).
The parameters for which the critical level of the
test was larger than 0.05 were rejected from the model –
see Tab. III. The factors of the model used in the analysis
are shown in Tab. IV.
Tab. III. Critical levels of the test for the factors rejected
from the death risk model function. p – critical level of the test
Factor p
Histological type of cancer 0.8893
Chemotherapy 0.8799
Coexisting diseases 0.4400
Haemoptysis 0.3594
A n a l y s i s  o f  t h e  e f f e c t i v e n e s s
o f  r a d i o t h e r a p y
The analysis performed indicated the very high effective-
ness of radiotherapy in the treatment of patients with the
advanced, non-small cell lung cancer. The improvement
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Fig. 3. Survival probability in the group of 803 patients irradiated palliati-
vely to mediastinum because of an advanced, non-small cell lung cancer
of the overall state and the reduction of the symptoms we-
re found in a significant part of the patients. In the case of
haemoptysis the improvement was reported by 91.7% of
the patients, in the case of pain – 74.2%, dyspnoea decre-
ased significantly in 78.9%, dysphagia in 77.4%, and
60.7% of the patients with the superior vena cava syn-
drome reported an improvement. This efficiency did not
have a confirmation in the radiological image of the dise-
ase. For the patients with haemoptysis, a total remission
of the disease, assessed in the chest X-ray, was observed
in only 1.8% of the patients, and a partial remission in
70.6%. For the patients with pain a total remission was fo-
und in 0.4% of the cases, and a partial one in 52.0%. In
the patients with dyspnoea the total remission was found
in 0.9% of the cases, and a partial one in 52.7%. In the
patients with dysphagia there were no cases with total
remission found, and a partial remission was found in
52.7%. In the patients with the superior vena cava syndro-
me no cases with total remission were found, and a partial
remission was found in 23.4% of the patients. The effi-
ciency of the types of fractionation applied in the analysis
was analysed with the use of the logit model. The results
can be found in Tab. V.
Progression after the treatment was found in 87 pa-
tients (10.8%). During the observation in 266 patients
(35.6%) the features of a spread outside the chest were
found. A vast majority of the patients had the features of
presence of the tumour in the chest during the last investi-
gation.
T h e  p r a c t i c a l  p r o g n o s t i c  i n d e x
To receive a more accurate tool for making a rational
therapeutical decision, we have identified six factors that
had the largest influence on the total survival in our ana-
lytical model. To this end we used the Cox proportional
risk model. The factors were merged to receive a single
prognostic index. The considered factors were:
– presence of the superior vena cava syndrome,
– performance status of the patient,
– spread of the disease outside the chest,
– selected symptoms (pain, dyspnoea, dysphagia).
Having the values of these symptoms for a specified
patient one can calculate the value of the prognostic index
i according to the following formula:
i = v + 0.8z + 0.5s + 0.5h + 0.4n + 0.3p (1)
where the symbols have a meaning and values described
in Tab. VI. The coefficients appearing in front of the sub-
sequent prognostic factors were determined in the multi-
variate Cox analysis – see Tab. IV. In the above formula
the values of the coefficients were rounded.
Tab. VI. Symbols and values in Expr. (1) for six factors determining
the total survival in the strongest way, 
used to construct the practical prognostic index
Symbol Factor Condition Value
v superior vena cava syndrome absent 0
present 1
z performance status score 1 or 2 0
(Zubrod) 3 or 4 1
s spread of the disease outside the absent 0
chest present 1
h dysphagia absent 0
present 1
n dyspnoea absent 0
present 1
p pain absent 0
present 1
The index found in this way makes it possible to qu-
alify the patient to one of four prognostic groups. The
qualification is performed by rounding the index i found
from the formula (1) to the nearest integer. The graphs of
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Tab. IV. Assessments of the Cox model parameters for the survival function. B – coefficient, S.E. – standard error,
p – critical value of the test, RR – relative risk
Factor B S.E. p RR
Pain 0.2831 0.1133 0.0125 1.3272
Dyspnoea 0.4473 0.1154 0.0001 1.5641
Superior vena cava syndrome 1.0413 0.1325 0.0000 2.8330
Dysphagia 0.5395 0.1707 0.0016 1.7152
Performance status score (Zubrod) 0.8206 0.0921 0.0000 2.2718
Spread disease 0.4892 0.2276 0.0316 1.6311
Tab. V. Efficiency of various methods of fractionation of the total dose in the analysed material (logit model)
Fractionation method Number of patients No. of patients with improvement (%) B S.E. p Quotient of chances
10 * 300 cGy 298 250 (83.9)
5 * 400 cGy 227 163 (71.8) 0.7152 0.2158 0.0009 2.0446
4 * 550 cGy 187 136 (72.7) 0.6692 0.2276 0.0033 1.9527
Other 91 56 (62.2) 1.1511 0.2685 0.0000 3.1615
total survivals for the four groups (graphs for the interme-
diate values of the index would lie between the respective
graphs for the integer values are shown in Fig. 4). The pa-
tients belonging to the first prognostic groups have the
best prognosis. If this group is taken as a reference level,
then the patients belonging to the second group have 1.3
times larger death risk, those from the third group – 2.5 ti-
mes larger risk, and those belonging to the fourth group –
5.5 times larger death risk. The formula (1) expresses the
fact that the presence of the superior vena cava syndrome
has the strongest negative influence on the prognosis,
the next worse factor is the bad performance status, and
the spread of the disease and the symptoms have a smal-
ler importance.
Discussion
In the present work an assessment of the results of pallia-
tive radiotherapy applied as the only therapy in 803 pa-
tients with an advanced, non-small cell lung cancer was
performed. The analysis has a retrospective character.
In the analysed group the probability of a 12-months
survival was 25%±1.5%, and that of a 24-months survival
was 8%±1%, median 6 months. These results are in con-
formity with those described in the literature: 1-year survi-
vals reach 23%, 2-years survivals – 10%, median 5 months
[20-22, 25, 26].
A survey of the literature indicates that the palliative
radiotherapy carried out in patients with the advanced
non-small cell lung cancer, with the symptoms related to
the growth of the tumour in the chest, brings an improve-
ment in 70-80% of the patients [3, 4, 7, 8, 13, 16, 17]. In
our material, an average of 75.3% of the patients felt the
decrease of the symptoms, from 60.7% to 91.7%, depen-
ding on the type of the symptoms, and 80 of them (10%)
returned to work. The fact that the symptomatic patients
should be qualified to such treatment is beyond discus-
sion. However, an important problem in the discussion on
the indications to the treatment is the group of patients in
which severe symptoms resulting from the disease in the
chest are not found. Such patients are about 30% of the
patients with the non-small cell lung cancer [4-8]. A half
of them do not need the irradiation of the disease in the
chest until the end of their lives, in the second half the
symptoms necessitating for a treatment appear sooner
or later [3, 4]. Unfortunately, during the first examination
it is not possible to qualify the patient to any of these
two groups. The majority of the authors decide to un-
dertake the palliative irradiation or to resign of it, by ta-
king into account the clinical advancement of the disease,
the overall performance status, the performance status
of the circulatory system and the respiratory system, pre-
vious illnesses and coexisting diseases. Finally, this deci-
sion, which is extremely important for the patient, is ma-
de in an arbitrary manner. On the one hand, resignation
of the palliative radiotherapy can deprive the patient of
a chance for long-term remission, and on the other, un-
dertaking the therapy in an asymptomatic patient with
an advanced disease, in a bad overall state, can deteriora-
te his quality of life and shorten his survival [7, 18, 19].
The decision is difficult, since, according to the literature,
the palliative radiotherapy has no influence on long-term
survival [9-11, 20-22].
In the analysis of the results of the palliative treat-
ment the problem of qualification to such treatment ap-
pears. Numerous studies indicate that the stage of the di-
sease, histological type of the cancer, size of the tumour,
age of the patients, previous chemotherapy have no influ-
ence on the results [7, 8, 12, 16, 17, 20, 22, 23, 28, 29].
The authors of the same papers point at the importance
of the performance status of the patient, and analyse in
case of which symptoms the largest improvement can be
expected. The majority univocally indicates that these
symptoms are: haemoptysis, pain, dyspnoea and cough.
These indications are in conformity with the present ana-
lysis.
In the discussion on the palliative radiotherapy of
the non-small cell lung cancer the questions on an optimal
dose fractionation method are present. The opinions on
the value of the total dose are contradictory. A part of the
authors observe no improvement of the survivals in ran-
domised studies in which the arm of total dose of 50 Gy
conventionally fractionated is compared to smaller do-
ses, with hypofractionation [10, 25, 26]. This does not
correlate with the results of other studies, where such
differences were observed [4, 13, 22, 27, 30].
In the vast majority of the clinics mainly the sympto-
matic patients are qualified to the palliative radiotherapy.
The investigations of this group of patients indicate a high
efficiency of large doses per fraction and short therapeu-
tical series [17, 21, 31]. In our material a trial of assessing
the efficiency of a number of fractionation methods of
the total dose was undertaken (Tab. VI). The probability
of an improvement was the largest for a single series of 10
fractions, 3 Gy each, and the smallest one was in the gro-
up of the so called other fractionation methods. This was
the administration of one or two fractions, 8 or 9 Gy
each, repeated after one-week break, according to the
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Fig. 4. Survival probability in the group of 803 patients irradiated
palliatively to mediastinum because of an advanced, non-small cell lung
cancer, in four prognostic groups, for the prognostic index according to
formula (1)
necessity. The fractionation type depended on the overall
status: patients with a worse overall status received single
fractions.
In the present analysis, six factors that determine
the overall survival in the strongest way were selected:
presence of the superior vena cava syndrome, overall per-
formance status of the patient, spread of the disease out-
side the chest, and the selected symptoms: pain, dyspno-
ea and dysphagia. These factors were merged in one
expression, which describes the prognostic index. This
proposition implies that the presence of all these factors
in a patient significantly deteriorates the prognosis. Ne-
vertheless, such situations can occur and we are obliged to
help the patient. According to the published studies, ra-
diotherapy with large fractions seems to be the best justi-
fied in such cases. The patients in good overall state and
without symptoms have large chances for a long survi-
val, according to the applied index (15% lives for 2 years,
10% – 3 years). Such considerations can give an answer in
the long-lasting discussion whether asymptomatic pa-
tients should be treated.
All the studies on palliative radiotherapy in patients
with non-small cell lung cancer univocally confirm its ve-
ry large effectiveness, and no other similarly effective
method is known. Maybe, the succeeding experience will
give an answer to the questions on the value of the ap-
plied total dose and the optimal method of its fractiona-
tion in the therapy of non-operative patients with non-
-small cell lung cancer.
Conclusions
1. Palliative radiotherapy improves the quality of life in c.
75% of patients with the advanced, non-small cell lung
cancer.
2. The largest improvement is observed in patients quali-
fied because of haemoptysis, dyspnoea, dysphagia and
pain in the chest.
3. The presence of the superior vena cava syndrome has
a largest negative influence on the prognosis.
4. Performance status is the most significant prognostic
factor in the qualification of patients with the advan-
ced, non-small cell lung cancer to palliative treatment.
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Sprostowanie
W Nowotworach 2001; 51; 27-33, w pracy „Dose intensity
of adjuvant CMF chemotherapy program for breast can-
cer” na stronie:
– 27 – w streszczeniu jest: „... (aRPI) of CMF reginect
has bees assed.”, a powinno byç: „... (aRDI) of CMF
regiment has been assessed”.
– 32 -, w Conclusions jest: „... regiment.”, a powinno
byç: „...regimen”
